I-Epiprobe igqityiwe phantse i-RMB 100 yezigidi ze-Series B zenkxaso-mali

Kutshanje, Shanghai Epiprobe Biotechnology Co., Ltd. (bhekisela "Epiprobe") ubhengeze ukuba sele igqibile phantse RMB 100 yezigidi kwi-Series B financing, nto leyo ityalwe ngokudibeneyo yinkunzi yemizi-mveliso, amaqonga otyalo-mali karhulumente kunye nenkampani ezidweliswe Yiyi Izabelo (SZ). : 001206).

Yasekwa ngo-2018, i-Epiprobe, njengomxhasi kunye novulindlela wokuhlolwa kwe-pan-cancer kwangethuba, lishishini lobugcisa obuphezulu obugxile ekuxilongweni kwemolekyuli yomhlaza kunye neshishini lamayeza achanekileyo.Ukwakha kwiqela eliphezulu leengcali ze-epigenetics kunye nokuqokelela okunzulu kwezemfundo, i-Epiprobe iphonononga intsimi yokufunyanwa komhlaza, ixhasa umbono "wokugcina wonke umntu kude nomhlaza," ezinikele ekubhaqweni kwangaphambili, ukuxilongwa kwangoko kunye nonyango lwakwangoko lomhlaza, ngaloo ndlela kuphuculwe ukusinda. izinga labaguli abanomhlaza ukomeleza impilo yoluntu lonke.

Emva kokumba iminyaka engama-20, iqela eliphambili le-Epiprobe lifumene ngokuzimeleyo uthotho lomhlaza we-Aligned General Methylated Epiprobes (TAGMe), ezixhaphakileyo kwimihlaza eyahlukeneyo, ngaloo ndlela yandisa kakhulu indawo yesicelo.

Ngokuphathelele iteknoloji yokufumanisa, i-pyrosequencing ngokuqhelekileyo ithathwa "njengomgangatho wegolide" wokufunyanwa kwe-methylation, nangona kunjalo ixhomekeke ekuguquleni i-bisulfite, kodwa ibonise ukusilela okufana nokuguqulwa okungazinzanga, ukuthotywa kwe-DNA lula, iimfuno eziphezulu zabaqhubi, kunye nokuxhomekeka kwizixhobo ezixabisekileyo.Oku kunqongophala kunciphisa ukusetyenziswa kwayo.I-Epiprobe, ngokwenza ukuphumelela kwezobugcisa, ngokuzimeleyo iye yavelisa iteknoloji yokufumanisa i-methylation entsha - i-Me-qPCR ngaphandle konyango lwe-bisulfite, okunciphisa iindleko kunye nokuphucula ukuzinza kokufumanisa kunye nokusebenza kweklinikhi, okwenza ukufumanisa kulula kwaye kulula.

I-Epiprobe, egxile kwiimpawu ze-pan-cancer eziphambili zenkampani kunye neendlela zokubona i-methylation, isebenzise amalungelo awodwa abenzi basekhaya nakwamanye amazwe angaphezu kwama-50, kwaye ifumene ugunyaziso lokuseka umenzi oqinileyo welungelo elilodwa lomenzi wechiza.

Okwangoku, i-Epiprobe isebenze ngokusondeleyo nezibhedlele eziphezulu ze-40 e-China, kubandakanywa neSibhedlele saseZhongshan, iSibhedlele soXolo lwaMazwe ngaMazwe kunye neSibhedlele seMpilo yaBantwana, kunye neSibhedlele saseChanghai njl njl, kwaye iphumeze uluhlu olubanzi lwemveliso kumhlaza wesibeleko sabasetyhini (kubandakanya umhlaza womlomo wesibeleko, umhlaza we-endometrial) , umhlaza we-urothelial (kuquka umhlaza wesinyi, umhlaza wesinyi, umhlaza wesibeleko), umhlaza wemiphunga, umhlaza wedlala lengqula, umhlaza wegazi kunye neminye imihlaza.Ukuqinisekiswa okuphindwe kabini kuye kwaphunyezwa kwiisampuli zeklinikhi ze-70,000 kunye neentlobo ze-25 zomhlaza.

Phakathi kweemveliso, kwiimveliso zokufumanisa umhlaza wendlela yokuzala yabasetyhini, ukuqinisekiswa okuphindwe kabini kuye kwaphunyezwa kwiisampulu zeklinikhi ezingaphezu kwama-40,000, kwaye uthotho lweziphumo zophando zipapashwe kwiijenali zezemfundo ezidumileyo ezifana noPhando lweCancer, iKlinikhi kunye neToliki yoNyango, kwaye ulingo lwezonyango olunamaziko amaninzi amakhulu luyaphunyezwa.Njengoko i-R&D iqhubela phambili kwaye izixhobo zikhula rhoqo, umbhobho wemveliso wenkampani ukhula ngokuthe chu.

UNksz. Hua Lin, i-CEO ye-Epiprobe uthe: “Kuliwonga lethu ukuqatshelwa nokuxhaswa ngamakomkhulu emizi-mveliso abalaseleyo.I-Epiprobe ibonakala ngokuqokelelwa kwayo okunzulu kwezemfundo, itekhnoloji eyodwa, kunye nophando oluluqilima lweklinikhi, oluphumelele ukuthembela kwamaqela amaninzi.Kule minyaka mine idlulileyo, iqela lenkampani kunye nokusebenza kuye kwaphucuka kakhulu.Kwiintsuku ezizayo, asizukwenza mzamo wokumema amaqabane anengqondo efanayo ukuba basebenzisane kwaye basebenze kunye, ngaloo ndlela sikhuthaza rhoqo i-R&D kunye nenkqubo yesicelo sobhaliso, kunye nokubonelela oogqirha kunye nezigulana ngezona nkonzo zisemgangathweni zovavanyo lomhlaza kunye iimveliso.”